Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

225
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
225
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

297
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
297
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

299
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
299
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

412
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
412
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

186
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
186
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ending TB by community empowerment: Challenges to access.

The Indian journal of tuberculosis·2026
Same author

Artificial intelligence driven innovation in tuberculosis drug discovery.

The Indian journal of tuberculosis·2026
Same author

Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

From seals to survival: "India's Cinderella stamp advocacy in the global tuberculosis eradication movement: A visual and historical examination".

The Indian journal of tuberculosis·2026
Same author

Landscape of metagenomics: fight against tuberculosis and other infectious disease in India.

The Indian journal of tuberculosis·2026
Same author

A diagnostic study of pulmonary and extra pulmonary tuberculosis by GeneXpert MTB/RIF assay in pediatric population.

The Indian journal of tuberculosis·2026

Related Experiment Video

Updated: Aug 20, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Drug resistant tuberculosis among elderly: Challenges.

K K Chopra1, S Matta2, V K Arora3

  • 1Director New Delhi Tuberculosis Centre, India.

The Indian Journal of Tuberculosis
|November 18, 2022
PubMed
Summary
This summary is machine-generated.

Geriatric patients face significant hurdles during multidrug-resistant (MDR) treatment initiation and continuation. Addressing factors like socioeconomic status, comorbidities, and adverse drug events is crucial for successful MDR therapy in older adults.

Keywords:
CavityDRTBElderlyGeriatricPrevalenceSocial factors

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.9K

Related Experiment Videos

Last Updated: Aug 20, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.9K

Area of Science:

  • Geriatric Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Multidrug-resistant (MDR) infections pose a growing threat, particularly to vulnerable populations.
  • Geriatric patients present unique physiological and anatomical changes that can complicate treatment.
  • Existing literature often overlooks the specific challenges faced by elderly individuals undergoing MDR treatment.

Purpose of the Study:

  • To identify and analyze the key challenges encountered by geriatric populations during multidrug-resistant (MDR) treatment.
  • To explore risk factors associated with initiating and managing MDR treatment in the elderly.
  • To highlight the impact of comorbidities and adverse drug events on treatment outcomes in older adults.

Main Methods:

  • Literature review focusing on studies involving geriatric patients and MDR treatment.
  • Analysis of risk factors, including patient demographics, socioeconomic status, and pre-existing conditions.
  • Examination of treatment-related issues such as adverse drug events and management of comorbidities.

Main Results:

  • Initiating MDR treatment in geriatric patients is hindered by factors including tobacco use, low socioeconomic status, prior disease history, treatment delays, and reduced mobility.
  • Drug-related adverse events and increased comorbidities significantly challenge ongoing MDR treatment in the elderly.
  • Geriatric susceptibility is amplified by anatomical/physiological changes, nutritional deficiencies, and co-existing health conditions.

Conclusions:

  • Geriatric populations experience multifaceted challenges during MDR treatment, requiring tailored management strategies.
  • Early identification and mitigation of risk factors are essential for successful MDR treatment initiation in older adults.
  • Comprehensive care addressing comorbidities, adverse events, and physiological changes is vital for optimizing MDR treatment outcomes in the elderly.